About Aspect Biosystems
Developing Bioprinted Tissue Therapeutics to transform how we treat some of the most elusive diseases.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Vancouver, British Columbia
- Founded
- 2013
- Company type
- Privately Held
Aspect Biosystems is a biotechnology company pioneering the development of a novel category of cellular medicines designed to replace or restore biological function and deliver curative therapies for some of the most elusive diseases. Aspect is developing these bioengineered cellular medicines by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering, and advanced biomaterials. Aspect is advancing its therapeutic pipeline across multiple endocrine and metabolic diseases, including diabetes and rare endocrine disorders.
Specialties
- bioprinting
- regenerative medicine
- therapeutic development
- and cell therapy
Company locations
2131 Manitoba St, Vancouver, British Columbia V5Y 0N7, CA
Locations listed on the company profile. These may include offices outside Canada, and not every location is hiring.
Business areas
- Health Care
- Biotechnology
- Life Science
- Artificial Intelligence (AI)
- 3D Printing
- Biotech & Pharmaceuticals
- Pharmaceutical and biotechnology
On LinkedIn
- Followers
- 28,596
- People linked to this company
- 146
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
252,846,526 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.